Showing 761-770 of 2501 results for "".
- CTAD 2025 Honors Takeshi Iwatsubo, MD, PhD with Lifetime Achievement Awardhttps://practicalneurology.com/news/ctad-2025-honors-takeshi-iwatsubo-md-phd-with-lifetime-achievement-award/2484692/Takeshi Iwatsubo, MD, PhD was recognized at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference as the recipient of this year’s Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. The award celebrates Dr. Iwatsubo’s decades of foundational work in Alzheime
- 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research Presented to Lars Lannfelt, MD, PhDhttps://practicalneurology.com/news/2024-lifetime-achievement-award-in-alzheimers-disease-therapeutic-research-presented-to-lars-lannfelt-md-phd/2470618/Lars Lannfelt, MD, PhD has been recognized as the recipient of the 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. Dr. Lannfelt was selected based on his pioneering work in Alzheim
- Barancik Prize Awarded to Sergio E. Baranzini, PhD at ACTRIMS 2024https://practicalneurology.com/news/barancik-prize-awarded-to-sergio-e-baranzini-phd-at-actrims-2024/2470413/This year, the National Multiple Sclerosis Society has awarded Sergio E. Baranzini, PhD the prestigious Barancik Prize for Innovation in Multiple Sclerosis (MS) Research. Professor Baranzini is a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco (UCS
- Award Recipients Recognized at 2025 International MDS Conferencehttps://practicalneurology.com/news/award-recipients-recognized-at-the-2025-international-congress-of-parkinsons-disease-and-movement-disorders/2483939/The International Parkinson’s Disease and Movement Disorders Society (MDS) has recognized recipients of the 2025 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The award
- Neurotrophic Factor-Secreting Stem Cell Treatment Improves Function in Progressive Multiple Sclerosishttps://practicalneurology.com/news/neurotrophic-factor-secreting-stem-cell-treatment-improves-function-in-progressive-multiple-sclerosis/2470024/As published in Multiple Sclerosis, off-the-shelf growth factor-secreting stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treatment of people with progressive multiple sclerosis (MS) im
- Autologous Mesenchymal Stem Cells Expressing Neurotrophic Factors Improved Function and Biomarkers in Progressive Multiple Sclerosishttps://practicalneurology.com/news/autologous-mesenchymal-stem-cells-expressing-neurotrophic-factors-improved-function-and-biomarkers-in-progressive-multiple-sclerosis/2469728/In a trial (NCT03799718) of autologous neurotrophic mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY), 18 individuals with progressive MS were treated, and 16 c
- Stem-Cell Treatment Improves Multiple Sclerosis Disability in Phase 2 Trialhttps://practicalneurology.com/news/phase-2-study-evaluating-msc-ntf-as-a-treatment-for-progressive-ms/2469545/In a phase 2 trial (NCT03799718), 3 repeated administrations of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treat
- FDA Advises More Clinical Data is Need for Potential ALS Stem Cell Treatmenthttps://practicalneurology.com/news/fda-advises-more-clinical-data-for-als-clinical-development-program/2469506/The Food and Drug Administration (FDA) gave feedback about autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), in a phase 3 clinical trial (
- Stem Cell Treatment Responses Fails to Reach Statistical Significance and Has High Placebo Response Ratehttps://practicalneurology.com/news/stem-cell-treatment-responses-fails-to-reach-statistical-significance-and-has-high-placebo-response-rate/2469434/In a phase 3 clinical trial (NCT03280056) of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), 34.7% of participants wi
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder